The evidence verdict for active patients

For active patients weighing up these two procedures, the balance of current evidence points clearly towards OATS. Three converging bodies of research — a controlled trial, a systematic review, and a large meta-analysis — all point in the same direction, with consistent findings across different study designs lending the evidence reasonable weight.

The most direct comparison comes from a randomised trial in 30 patients who had both an ACL tear and a small osteochondral defect (≤1.5 cm²). Patients who received OATS recorded significantly better scores on two validated knee-function scales — the Lysholm score and the IKDC score (patient-reported measures where higher numbers mean better function and less limitation) — at every follow-up point through 12 months (p<0.001).

A 2025 systematic review drawing on 18 studies and 475 younger and active patients reinforced this: OATS outperformed microfracture on both the radiographic quality of the repair tissue and rates of return to sport, while microfracture tended to be reserved for the smallest lesions in the cohort.

The most recent evidence comes from a 2026 meta-analysis of 736 patients with mean defect sizes of roughly 3.4 cm². OATS produced a mean IKDC improvement of 40.49 points, compared with 30.9 points for comparator repair techniques, with the advantage becoming more pronounced at longer follow-up.

No single long-term randomised trial has yet compared the two techniques exclusively in active adults, so a definitive verdict remains beyond what the evidence can currently support. The directional consistency across trial types, however, is difficult to dismiss.

Why the tissue type gap matters over time

The reason that performance gap widens over time rather than closing comes down to what each procedure actually deposits in the joint.

Microfracture works by puncturing the subchondral bone beneath the damaged cartilage, triggering a blood clot that eventually matures into repair tissue. That tissue is fibrocartilage — effectively a scar-like fill, made from a different collagen structure than the cartilage it replaces. It can look adequate on early imaging and feel reasonable in the first year or two. The problem is that fibrocartilage is poorly suited to the repetitive, high-load demands of athletic activity: it compresses and degrades in a way that native cartilage does not.

OATS takes a different approach entirely. Rather than prompting the body to generate a substitute, it transplants intact osteochondral plugs — bone with its original cartilage surface still attached — from a low-load-bearing part of the same knee into the damaged zone. The tissue arriving at the repair site is the mechanically appropriate kind from the outset.

Long-term data show the practical consequence. A 10-year RCT (47 patients) found that while microfracture produced genuine early improvement, its results deteriorated progressively beyond the two-year mark, whereas scaffold-augmented approaches remained stable. At five years, MRI scoring of repair tissue quality (MOCART) was more than twice as high in cell-based repair as in microfracture, with symptom scores tracking the same direction.

Short-term results from microfracture, in other words, can be misleading. The structural deficiency of the repair tissue does not disappear — it simply takes time to become apparent under load.

How lesion size shapes the decision

Defect size is the first variable surgeons assess, though it rarely settles the decision on its own.

Very small lesions (under 2 cm²). Microfracture was historically the standard starting point in this range. That position is now harder to defend: a 2025 multicentre double-blinded RCT found it offered no meaningful advantage over arthroscopic debridement alone for femoral lesions under 2 cm², while recording more complications — 10 events in five patients, against two events in two patients in the debridement arm.

The contested middle range (1–4 cm²). This is where most of the clinical debate sits, and where OATS is most applicable. A single plug typically covers roughly 1–2 cm²; arranging several in a mosaic pattern extends the technique to approximately 4 cm². For active patients across this band, the weight of current evidence — including the studies discussed in the opening section — increasingly favours OATS over microfracture.

Larger defects (above ~4 cm²). Autograft supply becomes the practical constraint here. Fresh osteochondral allograft or cell-based techniques such as ACI or MACI are generally more appropriate at this scale.

Lesion size, however, is only one input into the decision. Patient age, activity demand, bone quality, joint alignment, and concurrent injuries such as ACL damage all shape the final recommendation. A surgeon assessing these variables together may reach a different conclusion than the size threshold alone would suggest.

What OATS involves and the donor site trade-off

Practically speaking, OATS is performed as a single-stage procedure — either arthroscopically or through a small incision — usually lasting one to two hours. Cylindrical osteochondral plugs are harvested from the periphery of the femoral condyle or the trochlea, regions that carry relatively little load during normal movement, then press-fitted into the prepared defect. One plug typically fills a 1–2 cm² area; a mosaic of several plugs can address up to roughly 4 cm², as discussed in the previous section.

The harvest site introduces a trade-off that patients evaluating OATS should take seriously. Donor site morbidity is a documented risk: a minority of patients experience exertional knee pain at the graft collection point, and degenerative change at the harvest site has been recorded in some cases. This risk does not exist with microfracture. For athletes whose sport places repeated demand on the entire knee — not just the repaired zone — that distinction deserves an honest conversation with the treating surgeon before proceeding.

Survivorship figures for OATS are encouraging but should be read in context. An 88% survival rate at 15 years (mean follow-up 13.7 years) comes from a cohort treated specifically for spontaneous osteonecrosis of the knee, not the broader active-patient population. A 100% survivorship figure cited in bipolar lesion research reflects a single study in a narrowly defined group. Neither number is straightforwardly transferable to every candidate.

Outcome data also highlight the importance of the mechanical environment. Where bone alignment is suboptimal or a concurrent injury such as ACL damage is present, surgeons typically address those factors alongside or before OATS; the 12-month functional advantage seen in one RCT of patients with combined ACL tear and osteochondral damage was achieved with both conditions treated together. Rehabilitation after OATS generally involves a period of restricted weight-bearing — commonly six to eight weeks — with return-to-sport timelines varying according to defect size, the number of plugs used, and whether additional procedures were performed.

When microfracture or scaffold-augmented repair still fits

Plain microfracture, as the earlier sections make clear, is not the contemporary choice for active patients with meaningful defects. Its role has narrowed — but its augmented variant occupies a genuinely useful niche.

The clearest remaining case for marrow-stimulation techniques is where autograft harvest is impractical — because of anatomy, concurrent pathology, or defect morphology — or for very small lesions in lower-demand populations. Even that last indication has weakened following the 2025 RCT discussed in the lesion-size section.

Where marrow stimulation retains genuine relevance is when combined with a biologic scaffold — an approach referred to interchangeably as scaffold-augmented microfracture or AMIC (autologous matrix-induced chondrogenesis). Rather than leaving the marrow clot unsupported, the matrix guides cell migration and tissue organisation. A 10-year RCT of 47 patients found AMIC maintained stable Modified Cincinnati Knee Scores throughout follow-up, while plain microfracture deteriorated progressively after an initial two-year improvement.

For athletes where rapid return to sport is the overriding priority, augmented microfracture has produced compelling short-term results. A study of 49 professional athletes (aged 19–38) using a Hyalofast scaffold with early full load-bearing rehabilitation reported return to preinjury sport in approximately 2.5 to 3 months, with KOOS sports subscores reaching 99.8 out of 100 at one year — substantially faster than typical OATS rehabilitation. The longer-term durability picture in athletic populations remains less well established, and that gap is part of how surgeons weigh the trade-offs in practice.

Finding the right specialist for your situation

Technique selection here cannot be reduced to a decision tree. Lesion size is one input, but activity demand, bone quality, joint alignment, concurrent injuries such as ACL damage, and the surgeon's breadth of experience all shape the final recommendation. A specialist who works across the full cartilage repair spectrum — OATS, scaffold-augmented repair, ACI or MACI, and osteochondral allograft — is better placed to weigh those variables together than one whose practice centres on a single technique.

Three questions worth raising at consultation:

• What is the exact size and grade of my defect, and how does that narrow the options in my case? Size thresholds guide initial selection but are not absolute rules.
• Is donor site morbidity a realistic concern given how my sport loads the knee? For athletes who demand function across the whole joint, this deserves an honest answer rather than reassurance.
• What is a realistic return-to-sport timeline for the procedure you are recommending, and what individual factors might shift it? Timelines vary meaningfully between OATS, scaffold-augmented repair, and cell-based approaches.

For active patients with defects in the 1–4 cm² range, current evidence gives OATS the stronger long-term case — the honest conversation to have with a surgeon is about donor site risk, rehabilitation demands, and how long restricted weight-bearing is compatible with your situation. Search MSK lists cartilage repair specialists across the UK; filtering by region and specialty is a practical way to find a surgeon whose practice covers the range of techniques relevant to your situation.